Tribenzyltin carboxylates as anticancer drug candidates: Effect on the cytotoxicity, motility and invasiveness of breast cancer cell lines

被引:28
作者
Anasamy, Theebaa [1 ]
Thy, Chun Keng [2 ]
Lo, Kong Mun [2 ,3 ]
Chee, Chin Fei [2 ]
Yeap, Swee Keong [4 ]
Kamalidehghan, Behnam [5 ,6 ]
Chung, Lip Yong [1 ]
机构
[1] Univ Malaya, Dept Pharm, Fac Med, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Dept Chem, Fac Sci, Kuala Lumpur 50603, Malaysia
[3] Sunway Univ, Res Ctr Crystalline Mat, Petaling Jaya 47500, Selangor Darul, Malaysia
[4] Univ Putra Malaysia, Inst Biosci, Serdang 43400, Selangor Darul, Malaysia
[5] Shahid Beheshti Univ Med Sci, Sch Med, Dept Med Genet, Tehran 1983963113, Iran
[6] NIGEB, Med Genet Dept, Tehran 1497716316, Iran
关键词
Organotin complexes; Tribenzyltin carboxylates; Anticancer; Antimotility; Apoptosis; Breast cancer; PROTEASOME INHIBITORS; IN-VITRO; PYRROLIDINE DITHIOCARBAMATE; CASPASE ACTIVATION; ANTITUMOR-ACTIVITY; APOPTOSIS; COMPLEXES; TUMOR; FLUORINE; ASSAY;
D O I
10.1016/j.ejmech.2016.09.061
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This study seeks to investigate the relationship between the structural modification and bioactivity of a series of tribenzyltin complexes with different ligands and substitutions. Complexation with the N,N-diisopropylcarbamothioylsulfanylacetate or isonicotinate ligands enhanced the anticancer properties of tribenzyltin compounds via delayed cancer cell-cycle progression, caspase-dependent apoptosis induction, and significant reduction in cell motility, migration and invasion. Halogenation of the benzyl ring improved the anticancer effects of the tribenzyltin compounds with the N,N-diisopropylcarbamothioylsulfanylacetate ligand. These compounds also demonstrated far greater anticancer effects and selectivity than cisplatin and doxorubicin, which provides a rationale for their further development as anticancer agents. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:770 / 783
页数:14
相关论文
共 78 条
[51]   In vitro toxicity evaluation in the development of new anticancer drugs - genistein glycosides [J].
Popiolkiewicz, J ;
Polkowski, K ;
Skierski, JS ;
Mazurek, AP .
CANCER LETTERS, 2005, 229 (01) :67-75
[52]  
Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39
[53]   Fluorine in medicinal chemistry [J].
Purser, Sophie ;
Moore, Peter R. ;
Swallow, Steve ;
Gouverneur, Veronique .
CHEMICAL SOCIETY REVIEWS, 2008, 37 (02) :320-330
[54]   Evaluation of MCF10A as a Reliable Model for Normal Human Mammary Epithelial Cells [J].
Qu, Ying ;
Han, Bingchen ;
Yu, Yi ;
Yao, Weiwu ;
Bose, Shikha ;
Karlan, Beth Y. ;
Giuliano, Armando E. ;
Cui, Xiaojiang .
PLOS ONE, 2015, 10 (07)
[55]   Analysis of apoptosis by propidium iodide staining and flow cytometry [J].
Riccardi, Carlo ;
Nicoletti, Ildo .
NATURE PROTOCOLS, 2006, 1 (03) :1458-1461
[56]   Platinum complexes can inhibit matrix metalloproteinase activity: Platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12 [J].
Sasanelli, Rossella ;
Boccarelli, Angelina ;
Giordano, Domenico ;
Laforgia, Mariarita ;
Arnesano, Fabio ;
Natile, Giovanni ;
Cardellicchio, Cosimo ;
Capozzi, Maria A. M. ;
Coluccia, Mauro .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (15) :3434-3441
[57]   cis-Dichloroplatinum (II) complexes with aminomethylnicotmate and -isonicotinate ligands [J].
Schobert, R ;
Biersack, B .
INORGANICA CHIMICA ACTA, 2005, 358 (12) :3369-3376
[58]   Fluorine-containing taxoid anticancer agents and their tumor-targeted drug delivery [J].
Seitz, Joshua ;
Vineberg, Jacob G. ;
Zuniga, Edison S. ;
Ojima, Iwao .
JOURNAL OF FLUORINE CHEMISTRY, 2013, 152 :157-165
[59]  
Sheldrick G M., 2012, SHELXT
[60]   A short history of SHELX [J].
Sheldrick, George M. .
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2008, 64 :112-122